TITLE

Ketamine may block NMDA receptors in astrocytes causing a rapid antidepressant effect

AUTHOR(S)
Mitterauer, Bernhard J.; Hormuzdi, Sheriar; Tempia, Filippo; Bartos, Marlene
PUB. DATE
December 2012
SOURCE
Frontiers in Synaptic Neuroscience;Dec2012, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
88074486

 

Related Articles

  • Ketamine Infusion in Treatment Resistant Depression: A Case Report and Brief Review of The Literature. Sayar, Gökben Hızlı; Özten, Eylem; Savaş, Haluk A. // Journal of Mood Disorders;2015, Vol. 5 Issue 2, p78 

    The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may exhibit antidepressant effect. Previous studies of treatment-resistant depression reveal that ketamine infusions may result in a rapid antidepressant response with improvement usually sustained for several days. This case...

  • Mood disorders: Targeting protein synthesis for fast antidepressant action. Flight, Monica Hoyos // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p577 

    The article discusses the role of protein synthesis on the efficacy of antidepressant drugs. It references the study "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses," by A. E. Autry and colleagues in the June 15, 2011 issue. The authors analyze the mechanism...

  • Ketamine as a Novel Antidepressant: From Synapse to Behavior. Murrough, J W // Clinical Pharmacology & Therapeutics;Feb2012, Vol. 91 Issue 2, p303 

    Recent reports of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, even in treatment-resistant populations, have spurred translational therapeutic and neuroscience research aimed at elucidating ketamine's mechanism of action. This article...

  • Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Chaki, Shigeyuki; Fukumoto, Kenichi // Pharmaceuticals;2015, Vol. 8 Issue 3, p590 

    Recently, ketamine has been demonstrated to exert rapid-acting antidepressant effects in patients with depression, including those with treatment-resistant depression, and this discovery has been regarded as the most significant advance in drug development for the treatment of depression in over...

  • Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Shigeyuki Chaki; Kenichi Fukumoto // Pharmaceuticals;Sep2015, Vol. 8 Issue 3, p590 

    Recently, ketamine has been demonstrated to exert rapid-acting antidepressant effects in patients with depression, including those with treatment-resistant depression, and this discovery has been regarded as the most significant advance in drug development for the treatment of depression in over...

  • GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects. Burgdorf, Jeffrey; Zhang, Xiao-lei; Nicholson, Katherine L; Balster, Robert L; David Leander, J; Stanton, Patric K; Gross, Amanda L; Kroes, Roger A; Moskal, Joseph R // Neuropsychopharmacology;Apr2013, Vol. 38 Issue 5, p729 

    Recent human clinical studies with the NMDA receptor (NMDAR) antagonist ketamine have revealed profound and long-lasting antidepressant effects with rapid onset in several clinical trials, but antidepressant effects were preceded by dissociative side effects. Here we show that GLYX-13, a novel...

  • Ketamine and Glutamate Receptors: Potential Toxicity of General Anesthetics during Rapid Brain Development. Cheng Wang; Xuan Zhang; Xiaoju Zou; Paule, Merle G.; Slikker Jr., William // Central Nervous System Agents in Medicinal Chemistry;Jun2008, Vol. 8 Issue 2, p85 

    The amino acid L-glutamate is generally recognized as the major excitatory neurotransmitter of the mammalian central nervous system (CNS) and glutamate receptors play a major role in fast excitatory synaptic transmission. Nmethyl-D-aspartate (NMDA)-type glutamate receptors are widely distributed...

  • Blockade of N-Methyl-D-Aspartate Receptors by Ketamine Produces Loss of Postnatal Day 3 Monkey Frontal Cortical Neurons in Culture. Cheng Wang; Sadovova, Natalya; Hotchkiss, Charlotte; Xin Fu; Scallet, Andrew C.; Patterson, Tucker A.; Hanig, Joseph; Paule, Merle G.; Slikker Jr., William // Toxicological Sciences;May2006, Vol. 91 Issue 1, p192 

    Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is used as a general pediatric anesthetic. Recent data suggest that anesthetic drugs may cause neurodegeneration during development. The purpose of this study was to determine the robustness of ketamine-induced developmental...

  • Innovative approaches to treatment - refractory depression: The ketamine story. Rao, T. S. Sathyanarayana; Andrade, Chittaranjan // Indian Journal of Psychiatry;Apr-Jun2010, Vol. 52 Issue 2, p97 

    The authors discuss the therapeutic aspects of ketamine, an antidepressant drug. They cite various studies which focuses on the effectiveness of ketamine in treating patients with refractory depression. They describe ketamine as a chiral drug that has a greater affinity for the phencyclidine...

  • Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice. Ma, Xian-Cang; Dang, Yong-Hui; Jia, Min; Ma, Rui; Wang, Fen; Wu, Jin; Gao, Cheng-Ge; Hashimoto, Kenji // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major depressive disorder and bipolar depression. This rapid onset of action makes ketamine a highly attractive drug for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics